Cargando…

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment

How mixtures of immune cells associate with cancer cell phenotype and affect pathogenesis is still unclear. In 15 breast cancer gene expression datasets, we invariably identify three clusters of patients with gradual levels of immune infiltration. The intermediate immune infiltration cluster (Cluste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tekpli, Xavier, Lien, Tonje, Røssevold, Andreas Hagen, Nebdal, Daniel, Borgen, Elin, Ohnstad, Hege Oma, Kyte, Jon Amund, Vallon-Christersson, Johan, Fongaard, Marie, Due, Eldri Undlien, Svartdal, Lisa Gregusson, Sveli, My Anh Tu, Garred, Øystein, Frigessi, Arnoldo, Sahlberg, Kristine Kleivi, Sørlie, Therese, Russnes, Hege G., Naume, Bjørn, Kristensen, Vessela N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890706/ https://www.ncbi.nlm.nih.gov/pubmed/31796750 http://dx.doi.org/10.1038/s41467-019-13329-5

Ejemplares similares

Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
por: Lien, Tonje G., et al.
Publicado: (2021)

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
por: Ohnstad, Hege O., et al.
Publicado: (2017)

DNA methylation at enhancers identifies distinct breast cancer lineages
por: Fleischer, Thomas, et al.
Publicado: (2017)

Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
por: Tinholt, Mari, et al.
Publicado: (2020)

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
por: Røssevold, Andreas Hagen, et al.
Publicado: (2022)

Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
por: Dorraji, Esmaeil, et al.
Publicado: (2022)

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
por: Kyte, J. A., et al.
Publicado: (2020)

miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
por: Normann, Lisa Svartdal, et al.
Publicado: (2022)

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
por: Jernström, Sandra, et al.
Publicado: (2017)

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
por: Normann, Lisa Svartdal, et al.
Publicado: (2021)

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
por: Lindholm, Evita Maria, et al.
Publicado: (2019)

The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
por: Molloy, Timothy J, et al.
Publicado: (2011)

Subtype and cell type specific expression of lncRNAs provide insight into breast cancer
por: Bjørklund, Sunniva Stordal, et al.
Publicado: (2022)

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status
por: Zhao, Xi, et al.
Publicado: (2014)

miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors
por: Enerly, Espen, et al.
Publicado: (2011)

Correction: miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors
por: Enerly, Espen, et al.
Publicado: (2013)

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
por: Normann, Lisa Svartdal, et al.
Publicado: (2023)

Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
por: Jabeen, Shakila, et al.
Publicado: (2018)

LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer
por: Sas‐Chen, Aldema, et al.
Publicado: (2016)

The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
por: Silwal-Pandit, Laxmi, et al.
Publicado: (2015)

Combining Gene Signatures Improves Prediction of Breast Cancer Survival
por: Zhao, Xi, et al.
Publicado: (2011)

RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
por: Staaf, Johan, et al.
Publicado: (2022)

eEF2K—a new target in breast cancers with combined inactivation of p53 and PTEN
por: Russnes, Hege G, et al.
Publicado: (2014)

Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
por: Engebraaten, Olav, et al.
Publicado: (2012)

A systematic comparison of copy number alterations in four types of female cancer
por: Kaveh, Fatemeh, et al.
Publicado: (2016)

Correction to: A systematic comparison of copy number alterations in four types of female cancer
por: Kaveh, Fatemeh, et al.
Publicado: (2018)

Identifying In-Trans Process Associated Genes in Breast Cancer by Integrated Analysis of Copy Number and Expression Data
por: Aure, Miriam Ragle, et al.
Publicado: (2013)

ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
por: Kyte, J. A., et al.
Publicado: (2020)

Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors
por: Rye, Inga H., et al.
Publicado: (2018)

Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
por: Aure, Miriam Ragle, et al.
Publicado: (2015)

Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers
por: Kyte, Jon Amund
Publicado: (2022)

Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome
por: Naume, B, et al.
Publicado: (2005)

Quantitative Multigene FISH on Breast Carcinomas Identifies der(1;16)(q10;p10) as an Early Event in Luminal A Tumors
por: Rye, Inga H, et al.
Publicado: (2015)

Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
por: Fleischer, Thomas, et al.
Publicado: (2014)

DNA Copy Number Changes in Human Malignant Fibrous Histiocytomas by Array Comparative Genomic Hybridisation
por: Kresse, Stine H., et al.
Publicado: (2010)

The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells — A data description
por: Hongisto, Vesa, et al.
Publicado: (2014)

DNA copy number motifs are strong and independent predictors of survival in breast cancer
por: Pladsen, Arne V., et al.
Publicado: (2020)

Breast cancer quantitative proteome and proteogenomic landscape
por: Johansson, Henrik J., et al.
Publicado: (2019)

The multitude of molecular analyses in cancer: the opening of Pandora’s box
por: Russnes, Hege G, et al.
Publicado: (2014)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_g55h06m93u39haubk9if2bgar7